Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Insulin: The Receptor and Signaling Pathways

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Washout rate of cardiac <sup>123</sup>I-meta-iodobenzylguanidine and ischemic stroke outcome.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2024

Same author

Gut microbiome composition is associated with long-term disability worsening in multiple sclerosis.

Gut microbes·2023

Same author

Usefulness of the Neutrophil-to-Lymphocyte Ratio as a Predictor of Pneumonia and Urinary Tract Infection Within the First Week After Acute Ischemic Stroke.

Frontiers in neurology·2021

Same author

Opposite effects of one session of 1 Hz rTMS on functional connectivity between pre-supplementary motor area and putamen depending on the dyskinesia state in Parkinson's disease.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2021

Same author

The Role of Cerebral Hypoperfusion in Multiple Sclerosis (ROCHIMS) Trial in Multiple Sclerosis: Insights From Negative Results.

Frontiers in neurology·2020

Same author

Post-stroke infections associated with spleen volume reduction: A pilot study.

PloS one·2020

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

The insulin-like growth factor system in multiple sclerosis.

Daniel Chesik¹, Nadine Wilczak, Jacques De Keyser

¹Department of Neurology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.

International Review of Neurobiology

|May 29, 2007

Summary

Multiple sclerosis (MS) treatments fail in the progressive phase. Insulin-like growth factor-1 (IGF-1) shows promise for neuroprotection and myelin repair in MS, offering potential restorative therapies.

Related Experiment Videos

Last Updated: Jul 14, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Area of Science:

Neuroscience
Endocrinology
Immunology

Background:

Multiple sclerosis (MS) is a chronic central nervous system disorder involving inflammation, demyelination, and axonal loss.
Current MS therapies are ineffective during the disease's progressive phase, highlighting the need for neuroprotective and restorative treatments.

Purpose of the Study:

To explore the role of the Insulin-like Growth Factor (IGF) system in Multiple Sclerosis (MS) pathophysiology.
To review preclinical findings on the IGF system in MS models.
To discuss the therapeutic potential of IGF-1 for MS.

Main Methods:

Literature review of the IGF system's involvement in MS.
Analysis of preclinical data from MS models.
Discussion of IGF-1's neuroprotective and myelinogenic properties.

Main Results:

The IGF system, including IGF-1, IGF-2, and IGF-binding proteins (IGFBPs), plays a role in MS.
IGF-1 demonstrates neuroprotective effects and supports oligodendrocyte survival and myelination.
Preclinical studies suggest potential benefits of IGF-1 in MS models.

Conclusions:

The IGF system is implicated in the pathophysiology of Multiple Sclerosis.
IGF-1 exhibits significant neuroprotective and myelinogenic potential, making it a candidate for restorative MS therapies.
Further research into IGF-1-based therapies is warranted for progressive MS.